These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 36739246)

  • 21. A review of sucroferric oxyhydroxide for the treatment of hyperphosphatemia in patients receiving dialysis.
    Bousher A; Al-Makki A; Sutton J; Shepler B
    Clin Ther; 2014 Dec; 36(12):2082-2093. PubMed ID: 25450474
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum Phosphorus Management with Sucroferric Oxyhydroxide as a First-Line Phosphate Binder within the First Year of Hemodialysis.
    Medaura JA; Zhou M; Ficociello LH; Anger MS; Sprague SM
    Am J Nephrol; 2024; 55(2):127-135. PubMed ID: 38091973
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacodynamic Effects of Sucroferric Oxyhydroxide and Sevelamer Carbonate on Vitamin D Receptor Agonist Bioactivity in Dialysis Patients.
    Sprague SM; Covic AC; Floege J; Ketteler M; Botha J; Chong EM; Rastogi A
    Am J Nephrol; 2016; 44(2):104-12. PubMed ID: 27434393
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Management of serum phosphorus over a 1-year follow-up in patients on peritoneal dialysis prescribed sucroferric oxyhydroxide as part of routine care: a retrospective analysis.
    Kalantar-Zadeh K; Ficociello LH; Zhou M; Anger MS
    BMC Nephrol; 2024 Jun; 25(1):197. PubMed ID: 38886636
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Real-World Scenario Improvements in Serum Phosphorus Levels and Pill Burden in Peritoneal Dialysis Patients Treated with Sucroferric Oxyhydroxide.
    Kalantar-Zadeh K; Parameswaran V; Ficociello LH; Anderson L; Ofsthun NJ; Kwoh C; Mullon C; Kossmann RJ; Coyne DW
    Am J Nephrol; 2018; 47(3):153-161. PubMed ID: 29514139
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-world effectiveness of sucroferric oxyhydroxide in patients on chronic hemodialysis: A retrospective analysis of pharmacy data
.
    Coyne DW; Ficociello LH; Parameswaran V; Anderson L; Vemula S; Ofsthun NJ; Mullon C; Maddux FW; Kossmann RJ; Sprague SM
    Clin Nephrol; 2017 Aug; 88(8):59-67. PubMed ID: 28587714
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Iron kinetics following treatment with sucroferric oxyhydroxide or ferric citrate in healthy rats and models of anaemia, iron overload or inflammation.
    Floege J; Funk F; Ketteler M; Rastogi A; Walpen S; Covic AC; Sprague SM
    Nephrol Dial Transplant; 2020 Jun; 35(6):946-954. PubMed ID: 32259248
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dose-response efficacy and safety of PA21 in Japanese hemodialysis patients with hyperphosphatemia: a randomized, placebo-controlled, double-blind, Phase II study.
    Koiwa F; Terao A
    Clin Exp Nephrol; 2017 Jun; 21(3):513-522. PubMed ID: 27389681
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Changes in serum albumin and other nutritional markers when using sucroferric oxyhydroxide as phosphate binder among hemodialysis patients: a historical cohort study.
    Kalantar-Zadeh K; Ficociello LH; Parameswaran V; Athienites NV; Mullon C; Kossmann RJ; Coyne DW
    BMC Nephrol; 2019 Oct; 20(1):396. PubMed ID: 31664928
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A 6-Month clinical practice pilot study of sucroferric oxyhydroxide on nutritional status in patients on peritoneal dialysis.
    Perez L; You Z; Teitelbaum I; Andrews ES; Reddin R; Ramirez-Renteria L; Wilson G; Kendrick J
    BMC Nephrol; 2022 Jul; 23(1):245. PubMed ID: 35810296
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sucroferric Oxyhydroxide in Maintenance Hemodialysis: A Retrospective, Comparative Cohort Study.
    Coyne DW; Ficociello LH; Parameswaran V; Rosen MM; Mullon C; Kossmann RJ; Sprague SM
    Kidney Med; 2020; 2(3):307-316. PubMed ID: 32734250
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sucroferric oxyhydroxide decreases serum phosphorus level and fibroblast growth factor 23 and improves renal anemia in hemodialysis patients.
    Shima H; Miya K; Okada K; Minakuchi J; Kawashima S
    BMC Res Notes; 2018 Jun; 11(1):363. PubMed ID: 29884226
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of sucroferric oxyhydroxide in the treatment of hyperphosphataemia in chronic kidney disease in Asturias. FOSFASTUR study.
    Sanchez-Alvarez JE; Astudillo Cortés E; Seras Mozas M; García Castro R; Hidalgo Ordoñez CM; Andrade López AC; Ulloa Clavijo C; Gallardo Pérez A; Rodríguez Suarez C
    Nefrologia (Engl Ed); 2021; 41(1):45-52. PubMed ID: 36165361
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Proton pump inhibitors may hinder hypophosphatemic effect of lanthanum carbonate, but not of ferric citrate hydrate or sucroferric oxyhydroxide, in hemodialysis patients.
    Minakuchi H; Yoshida T; Kaburagi N; Fujino T; Endo S; Takemitsu TY; Yamashita N; Itoh H; Oya M
    Ren Fail; 2020 Nov; 42(1):799-806. PubMed ID: 32779954
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety and effectiveness of ferric citrate hydrate in serum phosphorus management of patients with chronic kidney disease: a long-term, real-world, observational, post-marketing surveillance study.
    Yokoyama K; Hashimoto T; Okuda Y; Matsumoto Y; Ito K; Yamada R; Susai H; Nishino N
    Clin Exp Nephrol; 2022 Jul; 26(7):688-699. PubMed ID: 35258721
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chronic Therapy with Sucroferric Oxyhydroxide Does Not Affect Iron and Anemia Markers in Dialysis Patients.
    Lioulios G; Stangou M; Sarafidis PA; Tsouchnikas I; Minasidis I; Vainas A; Faitatzidou D; Sampani E; Papagianni A
    Blood Purif; 2020; 49(4):440-447. PubMed ID: 32050202
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of sucroferric oxyhydroxide and sevelamer carbonate on chronic kidney disease-mineral bone disorder parameters in dialysis patients.
    Ketteler M; Sprague SM; Covic AC; Rastogi A; Spinowitz B; Rakov V; Walpen S; Floege J
    Nephrol Dial Transplant; 2019 Jul; 34(7):1163-1170. PubMed ID: 29846719
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-Term Assessment of the Safety and Efficacy of PA21 (Sucroferric Oxyhydroxide) in Japanese Hemodialysis Patients With Hyperphosphatemia: An Open-Label, Multicenter, Phase III Study.
    Koiwa F; Yokoyama K; Fukagawa M; Akizawa T
    J Ren Nutr; 2017 Sep; 27(5):346-354. PubMed ID: 28550969
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Hyperphosphatemia in dialysis: which binder?].
    Alfieri C; Malberti F; Mazzaferro S; Gallieni M; Russo D; Messa P; Cozzolino M
    G Ital Nefrol; 2018 Sep; 35(5):. PubMed ID: 30234231
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of sucroferric oxyhydroxide on the oral and intestinal microbiome in hemodialysis patients.
    Abdelbary MMH; Kuppe C; Michael SS; Krüger T; Floege J; Conrads G
    Sci Rep; 2022 Jun; 12(1):9614. PubMed ID: 35689007
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.